By buying units of this REIT, small investors can now own a portion of the booming, rent-yielding retail sector.

Read More

​ By buying units of this REIT, small investors can now own a portion of the booming, rent-yielding retail sector. By buying units of this REIT, small investors can now own a portion of the booming, rent-yielding retail sector.  Moneycontrol Latest News Read More  

By buying units of this REIT, small investors can now own a portion of the booming, rent-yielding retail sector.

Qin Gang met Nick Burns in Beijing on May 8, 2023. The foreign minister said it is imperative to stabilise Sino-US relations after a series of “erroneous words and deeds” put ties into a deep freeze. Relations between the two have been strained over the Taiwan issue. 

Read More

​ Qin Gang met Nick Burns in Beijing on May 8, 2023. The foreign minister said it is imperative to stabilise Sino-US relations after a series of “erroneous words and deeds” put ties into a deep freeze. Relations between the two have been strained over the Taiwan issue.  Qin Gang met Nick Burns in Beijing on May 8, 2023. The foreign minister said it is imperative to stabilise Sino-US relations after a series of “erroneous words and deeds” put ties into a deep freeze. Relations between the two have been strained over the Taiwan issue.   Moneycontrol Latest News Read More  

Qin Gang met Nick Burns in Beijing on May 8, 2023. The foreign minister said it is imperative to stabilise Sino-US relations after a series of “erroneous words and deeds” put ties into a deep freeze. Relations between the two have been strained over the Taiwan issue. 

The actor, who has backed startups in the health and sports space, is looking to further invest in new companies with a basic cash flow. He says that for him the founders and their ideas are most important.

Read More

​ The actor, who has backed startups in the health and sports space, is looking to further invest in new companies with a basic cash flow. He says that for him the founders and their ideas are most important. The actor, who has backed startups in the health and sports space, is looking to further invest in new companies with a basic cash flow. He says that for him the founders and their ideas are most important.  Moneycontrol Latest News Read More  

The actor, who has backed startups in the health and sports space, is looking to further invest in new companies with a basic cash flow. He says that for him the founders and their ideas are most important.

After 5-7 years of underperformance, the fall in the profit pool share has been quite stark for sectors such as auto, pharma, cement and gas utilities. Thus, they present a better margin of safety, says Krishnan

Read More

​ After 5-7 years of underperformance, the fall in the profit pool share has been quite stark for sectors such as auto, pharma, cement and gas utilities. Thus, they present a better margin of safety, says Krishnan After 5-7 years of underperformance, the fall in the profit pool share has been quite stark for sectors such as auto, pharma, cement and gas utilities. Thus, they present a better margin of safety, says Krishnan  Moneycontrol Latest News Read More  

After 5-7 years of underperformance, the fall in the profit pool share has been quite stark for sectors such as auto, pharma, cement and gas utilities. Thus, they present a better margin of safety, says Krishnan

With ONDC, the government hopes to increase e-commerce penetration in the country to 25 percent in the next two years

Read More

​ With ONDC, the government hopes to increase e-commerce penetration in the country to 25 percent in the next two years With ONDC, the government hopes to increase e-commerce penetration in the country to 25 percent in the next two years  Moneycontrol Latest News Read More  

With ONDC, the government hopes to increase e-commerce penetration in the country to 25 percent in the next two years

For the quarter ended March 31, 2023, the company recorded a 140 per cent increase in consolidated profit after tax and non-controlling interest at Rs 137 crores against Rs 57 crores in the previous year. Consolidated revenue from operations for the March 2023 quarter grew to Rs 1,183 crore from Rs 859 crore in the same period of last year.

Read More

​ For the quarter ended March 31, 2023, the company recorded a 140 per cent increase in consolidated profit after tax and non-controlling interest at Rs 137 crores against Rs 57 crores in the previous year. Consolidated revenue from operations for the March 2023 quarter grew to Rs 1,183 crore from Rs 859 crore in the same period of last year. For the quarter ended March 31, 2023, the company recorded a 140 per cent increase in consolidated profit after tax and non-controlling interest at Rs 137 crores against Rs 57 crores in the previous year. Consolidated revenue from operations for the March 2023 quarter grew to Rs 1,183 crore from Rs 859 crore in the same period of last year.  Moneycontrol Latest News Read More  

For the quarter ended March 31, 2023, the company recorded a 140 per cent increase in consolidated profit after tax and non-controlling interest at Rs 137 crores against Rs 57 crores in the previous year. Consolidated revenue from operations for the March 2023 quarter grew to Rs 1,183 crore from Rs 859 crore in the same period of last year.

Mankind Pharma IPO: The company is almost entirely focussed in India. The domestic market contributed 97.60 percent to the company#39;s revenue from operations in FY22

Read More

​ Mankind Pharma IPO: The company is almost entirely focussed in India. The domestic market contributed 97.60 percent to the company#39;s revenue from operations in FY22 Mankind Pharma IPO: The company is almost entirely focussed in India. The domestic market contributed 97.60 percent to the company#39;s revenue from operations in FY22  Moneycontrol Latest News Read More  

Mankind Pharma IPO: The company is almost entirely focussed in India. The domestic market contributed 97.60 percent to the company#39;s revenue from operations in FY22

Officials said digital certificates will bring more security, transparency and efficiency while reducing manual verification processes.

Read More

​ Officials said digital certificates will bring more security, transparency and efficiency while reducing manual verification processes. Officials said digital certificates will bring more security, transparency and efficiency while reducing manual verification processes.  Moneycontrol Latest News Read More  

Officials said digital certificates will bring more security, transparency and efficiency while reducing manual verification processes.

Brokerage firm Macquarie Research has given Mankind Pharma Ltd an outperform rating with a target price of Rs 1400 per share, indicating a potential upside of 29.6% from its issue price of Rs 1068 per share.

Read More

​ Brokerage firm Macquarie Research has given Mankind Pharma Ltd an outperform rating with a target price of Rs 1400 per share, indicating a potential upside of 29.6% from its issue price of Rs 1068 per share. Brokerage firm Macquarie Research has given Mankind Pharma Ltd an outperform rating with a target price of Rs 1400 per share, indicating a potential upside of 29.6% from its issue price of Rs 1068 per share.  Moneycontrol Latest News Read More  

Brokerage firm Macquarie Research has given Mankind Pharma Ltd an outperform rating with a target price of Rs 1400 per share, indicating a potential upside of 29.6% from its issue price of Rs 1068 per share.

Brokerage firm Macquarie Research has given Mankind Pharma Ltd an outperform rating with a target price of Rs 1400 per share, indicating a potential upside of 29.6% from its issue price of Rs 1068 per share.

Read More

​ Brokerage firm Macquarie Research has given Mankind Pharma Ltd an outperform rating with a target price of Rs 1400 per share, indicating a potential upside of 29.6% from its issue price of Rs 1068 per share. Brokerage firm Macquarie Research has given Mankind Pharma Ltd an outperform rating with a target price of Rs 1400 per share, indicating a potential upside of 29.6% from its issue price of Rs 1068 per share.  Moneycontrol Latest News Read More  

Brokerage firm Macquarie Research has given Mankind Pharma Ltd an outperform rating with a target price of Rs 1400 per share, indicating a potential upside of 29.6% from its issue price of Rs 1068 per share.